Shots:

• EDDC will receive an initial upfront payment and downstream clinical and commercial milestone payments, along with royalties on net product sales. Everest holds full rights to sub-license EDDC-2214 and will also receive full technology transfer
• Everest will get exclusive global rights to EDDC's series of 3CL protease inhibitors that demonstrated potent in-vitro activity against SAR-CoV-2 and its variants, as well as other coronaviruses like MERS.
• EDDC-2214 is a novel and potent SARS-CoV-2 3CL protease inhibitor which exhibits better in-vitro potency and pre-clinical oral bioavailability as compared to other oral COVID-19 antivirals. The clinical trials evaluating EDDC-2214 are anticipated to initiate later in 2022

Ref: PR Newswire | Image: PR Newswire